Morrow Michael M
Known title: DirectorCIK: 0001715897
Associated companies
Transaction History
| CBT | ▲ Buy | Grant | 2,298 | $0 | 1/8/2026 | View on chart |
| CBT | ▲ Buy | Grant | 1,788 | $0 | 1/10/2025 | View on chart |
| CBT | ▲ Buy | Grant | 2,035 | $0 | 1/11/2024 | View on chart |
| CBT | ▲ Buy | Grant | 1,854 | $0 | 1/12/2023 | View on chart |
| CBT | ▲ Buy | Grant | 2,254 | $0 | 1/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Cabot Corp to Report Q4 FY2026 Results
Cabot Corporation will release its fourth‑quarter and full‑year 2026 operating results on Friday. The announcement follows a period of steady performance and may influence the stock’s near‑term movement. A recent article highlighted the company’s dividend yield of 2.06% and earnings guidance as key factors for investors. The stock is currently trading near its 52‑week low and close to a support level of $74.80.
Cabot Corp to Report Q4 FY2026 Results. Cabot Corporation will release its fourth‑quarter and full‑year 2026 operating results on Friday. The announcement follows a period of steady performance and may influence the stock’s near‑term movement. A recent article highlighted the company’s dividend yield of 2.06% and earnings guidance as key factors for investors. The stock is currently trading near its 52‑week low and close to a support level of $74.80.